Suppr超能文献

小胆管原发性硬化性胆管炎患者的长期预后良好。

Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis.

作者信息

Björnsson E, Boberg K M, Cullen S, Fleming K, Clausen O P, Fausa O, Schrumpf E, Chapman R W

机构信息

Department of Internal Medicine, Section of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden.

出版信息

Gut. 2002 Nov;51(5):731-5. doi: 10.1136/gut.51.5.731.

Abstract

BACKGROUND

Patients with cholestatic liver function tests and histological features of primary sclerosing cholangitis (PSC) but a normal cholangiogram are considered to have small duct PSC. The natural history of this condition is unknown.

METHODS

Thirty three patients with small duct PSC were identified among patients admitted for diagnostic workup of cholestatic liver function tests in one centre in the UK (Oxford) and one centre in Norway (Oslo). A total of 260 patients with large duct PSC were compared, and prognosis in terms of death, cholangiocarcinoma, biochemical features, histological features, and symptoms analysed.

RESULTS

Mean age at diagnosis was 38 years and 39 years in small duct and large duct PSC, respectively. Mean follow up was 106 months in small duct and 105 months in large duct patients. Four patients originally considered to have small duct developed large duct PSC. Two of these underwent liver transplantation during follow up. Of the remainder who did not develop large duct PSC, two patients died during follow up: one of liver failure and the other of cardiac death unrelated to her liver disease. A total of 122 (47%) large duct patients either required liver transplantation (34 patients) or died (88 patients). Small duct patients had a significantly better survival compared with large duct patients. Among small duct patients, none developed cholangiocarcinoma compared with 28 of 260 (11%) large duct patients.

CONCLUSIONS

Patients with small duct PSC seem to have a good prognosis in terms of survival and development of cholangiocarcinoma. Small duct PSC progresses to large duct PSC in a small proportion of patients.

摘要

背景

肝功能检查显示胆汁淤积且具有原发性硬化性胆管炎(PSC)的组织学特征,但胆管造影正常的患者被认为患有小胆管PSC。这种疾病的自然史尚不清楚。

方法

在英国牛津的一个中心和挪威奥斯陆的一个中心,从因胆汁淤积性肝功能检查而入院接受诊断检查的患者中,识别出33例小胆管PSC患者。总共对260例大胆管PSC患者进行了比较,并分析了死亡、胆管癌、生化特征、组织学特征和症状方面的预后情况。

结果

小胆管PSC和大胆管PSC患者诊断时的平均年龄分别为38岁和39岁。小胆管患者的平均随访时间为106个月,大胆管患者为105个月。最初被认为是小胆管PSC的4例患者发展为大胆管PSC。其中2例在随访期间接受了肝移植。在其余未发展为大胆管PSC的患者中,2例在随访期间死亡:1例死于肝衰竭,另1例死于与肝病无关的心脏疾病。总共122例(47%)大胆管患者要么需要肝移植(34例),要么死亡(88例)。小胆管患者的生存率明显高于大胆管患者。在小胆管患者中,无人发生胆管癌,而260例大胆管患者中有28例(11%)发生胆管癌。

结论

小胆管PSC患者在生存和胆管癌发生方面似乎预后良好。一小部分小胆管PSC患者会进展为大胆管PSC。

相似文献

2
Small-duct primary sclerosing cholangitis.
Curr Gastroenterol Rep. 2009 Feb;11(1):37-41. doi: 10.1007/s11894-009-0006-6.
3
The natural history of small-duct primary sclerosing cholangitis.
Gastroenterology. 2008 Apr;134(4):975-80. doi: 10.1053/j.gastro.2008.01.042. Epub 2008 Jan 17.
4
Small-duct primary sclerosing cholangitis. A single-center seven-year experience.
Dig Dis Sci. 2005 Feb;50(2):324-6. doi: 10.1007/s10620-005-1604-2.
5
Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis.
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1380-1389. doi: 10.1016/j.bbadis.2017.09.012. Epub 2017 Sep 22.
10
Management of primary sclerosing cholangitis.
Minerva Gastroenterol Dietol. 2009 Jun;55(2):163-72.

引用本文的文献

1
Unique clinical, morphological, and molecular characteristics of tumors associated with PSC-IBD.
Virchows Arch. 2025 Apr;486(4):651-661. doi: 10.1007/s00428-025-04072-y. Epub 2025 Mar 19.
2
Management of primary sclerosing cholangitis: Current state-of-the-art.
Hepatol Commun. 2024 Nov 15;8(12). doi: 10.1097/HC9.0000000000000590. eCollection 2024 Dec 1.
3
Update on the optimisation of endoscopic retrograde cholangiography (ERC) in patients with primary sclerosing cholangitis.
Frontline Gastroenterol. 2023 Sep 12;15(1):74-83. doi: 10.1136/flgastro-2023-102491. eCollection 2024 Jan.
4
Risk Stratification in Primary Sclerosing Cholangitis: Does Size Matter?
Dig Dis Sci. 2024 Apr;69(4):1083-1087. doi: 10.1007/s10620-023-08262-z. Epub 2024 Feb 12.
5
Primary Sclerosing Cholangitis Limited to Intrahepatic Bile Ducts Has Distinctly Better Prognosis.
Dig Dis Sci. 2024 Apr;69(4):1421-1429. doi: 10.1007/s10620-023-08260-1. Epub 2024 Feb 12.
7
Cellular and transcriptional heterogeneity in the intrahepatic biliary epithelium.
Gastro Hep Adv. 2023;2(1):108-120. doi: 10.1016/j.gastha.2022.07.015. Epub 2022 Aug 5.
9
Hepatobiliary manifestations in inflammatory bowel disease: A practical approach.
World J Hepatol. 2022 Feb 27;14(2):319-337. doi: 10.4254/wjh.v14.i2.319.
10
Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis.
World J Gastrointest Oncol. 2021 Oct 15;13(10):1336-1366. doi: 10.4251/wjgo.v13.i10.1336.

本文引用的文献

1
Variant forms of cholestatic diseases involving small bile ducts in adults.
Am J Gastroenterol. 2000 May;95(5):1130-8. doi: 10.1111/j.1572-0241.2000.01999.x.
2
Idiopathic adulthood ductopenia: case report and review of the literature.
Arch Intern Med. 2000 Apr 10;160(7):1033-6. doi: 10.1001/archinte.160.7.1033.
4
Intrahepatic bile duct loss in primary sclerosing cholangitis: a quantitative study.
Histopathology. 1998 May;32(5):449-53. doi: 10.1046/j.1365-2559.1998.00399.x.
5
Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease.
Scand J Gastroenterol. 1997 Jun;32(6):604-10. doi: 10.3109/00365529709025107.
6
Primary sclerosing cholangitis in Japan--analysis of 192 cases.
J Gastroenterol. 1997 Feb;32(1):134-7. doi: 10.1007/BF01213311.
9
Prognostic value of cholangiography in primary sclerosing cholangitis.
Eur J Gastroenterol Hepatol. 1995 Mar;7(3):251-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验